Immunogenicity and safety of two doses of catch-up immunization with Haemophilus influenzae type b conjugate vaccine in Indian children living with HIV

Highlights • The optimal schedule for HibCV in children with HIV is unclear in settings with limited access to ART. • The recommended schedule of 1 dose of HibCV may be inadequate in such settings. • 76% of HIV infected children 2–15 years mounted an immune response following 2-doses of HibCV. • Immune responses were adequate even among children with viral loads >100,000 copies/mL. • Anti-Hib-PRP IgG ≥ 3.3 μg/mL provided protection against Hib NP colonization in children with HIV.